360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Regeneron

Type: Company

Name: Regeneron

First reported 12 hours ago - Updated 12 hours ago - 1 reports

Nationstar Mortgage Holdings Inc

IBD 50 Stocks Delivering Strong Earnings, Sales Gains

Posted 06:51 PM ETWith earnings season winding down, a large number of companies have reported quarterly earnings above views.Yet sales have come in below expectations for many firms.When evaluating companies, make sure they have strong growth in their ... [Published Investors Business Daily - 12 hours ago]

Entities: Eylea, Stocks, Fuel Card, Nationstar Mortgage Holdings Inc, FleetCor Technologies Inc

First reported 22 hours ago - Updated 22 hours ago - 1 reports

General Motors Company

Top Pre-Market Stock Upgrades/Downgrades May 17, 2013

UPGRADESGeneral Motors (NYSE:GM) upgraded to Buy from Underperform at CLSA ? CLSA upgraded General Motors two notches to Buy from Underperform and raised its price target for shares to $40 from $31. The firm is positive on GM?s product cycle in the U.S. ... [Published Wall Street Pit - 22 hours ago]

Entities: General Motors Company, New York Stock Exchange, Applied Materials Inc

First reported May 16 2013 - Updated 22 hours ago - 2 reports

Late-Day Pullback Leads To Lower Close On Wall Street

WASHINGTON (dpa-AFX) - After seeing modest strength earlier in the session, stocks came under pressure going into the close of Thursday. A disappointing batch of U.S. economic data weighed on the markets along with comments from a Federal Reserve off ... [Published FinanzNachrichten.de - May 16 2013]

Entities: Wall Street, Biotechnology, S&P 500, Regeneron

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Regeneron Q1 net income increases

Regeneron Pharmaceuticals, Inc., an integrated biopharmaceutical company, has reported that net income for the first quarter ended March 31, 2013 was $98.87 million, or $0.90 per diluted share, compared to $11.65 million, or $0.11 per diluted share, for ... [Published Individual.com - May 17 2013]

Entities: Regeneron, Eylea, Regeneron Pharmaceuticals Inc, Bayer HealthCare

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Only 12% of Public Biotechs are Profitable

Only 12% of Public Biotechs are Profitable Of the 286 biotech companies trading on public exchanges today, 241 focus on drug development, a slight drop in numbers from last year.* Of these 241 in the biopharmaceutical space, only 28 (12%) had both ... [Published I Am Biotech - May 16 2013]

Entities: Regeneron, Vertex, Acquisition

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Regeneron acquires rights to two antibodies for use in ophthalmology

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, has expanded its ophthalmology portfolio by acquiring full exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration ... [Published Individual.com - May 16 2013]

Entities: Antibody, Regeneron, Ophthalmology

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Sanofi SA

Sanofi/Regeneron begin two more trials for RA drug

Sanofi and longtime partner Regeneron Pharmaceuticals have started enrolling patients for two new late-stage trials of their investigational rheumatoid arthritis treatment sarilumab.The Phase III trials, which form part of a programme that consists of ... [Published Pharma Times - May 16 2013]

Entities: Sanofi SA, Regeneron, Patient

First reported May 16 2013 - Updated May 16 2013 - 2 reports

Sanofi, Regeneron begin patient enrollment in OMPARE & ASCERTAIN trials of sarilumab in RA

Sanofi and Regeneron Pharmaceuticals, Inc., a leading science-based biopharmaceutical company, announced that the COMPARE and ASCERTAIN trials of sarilumab, the first fully human monoclonal antibody directed against the IL-6 receptor, which is delivered ... [Published PharmaBiz - May 16 2013]

Entities: Regeneron, IL-6, Sanofi SA, Patient

First reported May 14 2013 - Updated May 14 2013 - 2 reports

Video: Cramer's Six in 60: Monster Beverage, Clorox & More

Cramer shares six stocks to watch, and reveals them in under 60 seconds, including Kroger, Regeneron, and Procter & Gamble.Share This:BusinessSen. Franken Wants New Board to Oversee Ratings AgenciesCNBCIs Privacy a Thing of the Past?CNBCMay 13, 2013Sen. ... [Published NBCNews.com - May 14 2013]

Entities: Monster Beverage Corporation, Clorox Company, Regeneron, Procter & Gamble

First reported May 14 2013 - Updated May 14 2013 - 1 reports

Nominate a Local Biz for 914INC.’s First-Ever Excellence in Small Business Awards

PLUS: New Rochelle Mayor Noam Bramson Wins Democratic Bid for County Executive; White Plains Hospital Honored by American Heart Association; and more.Know of an outstanding small business in Westchester, or own/work at one yourself? Nominate your community-fixture ... [Published Westchester Magazine - May 14 2013]

Entities: Rob Astorino, Westchester County, Regeneron, Tappan Zee Constructors

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Is Regeneron A Value Pick In The Pharma Sector?

Regeneron Pharmaceuticals (NASDAQ: REGN), a mid-sized biotechnology company, is a classic case of how FDA approval of a single drug can transform the fortunes of a biotech company. The company's stock has returned more than 100% to investors in the last ... [Published Seeking Alpha - May 13 2013]

Entities: Regeneron, Eylea, Cholesterol

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Regeneron to Present at Upcoming 2013 Investor Conferences

5 minutes ago, 12:27am (ET) 05/13/2013 Close-Up MediaRegeneron Pharmaceuticals, Inc. will webcast management presentations at the following investor conferences:-UBS Global Healthcare Conference on May 20. The presentation is scheduled for 10 a.m. Eastern ... [Published Zecco - May 13 2013]

Entities: Regeneron, Healthcare Conference, Regeneron Pharmaceuticals Inc, UBS AG, Goldman Sachs Group Inc

Quotes

...Amgen recently announced that it "will present data from several studies of both pipeline and marketed products at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4 in Chicago." Additional disclosure: I do not warrant the accuracy of any data provided in this article or in the referenced DCF spreadsheet...

Here's Why Amgen Shares Are Worth $117 To $126 Today [Published Seeking Alpha - 7 hours ago]

"EYLEA sales in the US continue to enjoy strong growth and we are raising our estimate of full year US EYLEA net sales to $1.25 to $1.325 billion in 2013. The ex-US launch of EYLEA by our partner, Bayer HealthCare, is also going very well and resulted in a positive contribution to our earnings this quarter. Our broad, late-stage pipeline is making progress. We expect our first data from the alirocumab Phase III program for reducing LDL cholesterol in the second half of 2013. We reported positive data with our IL-4R inhibitor, dupilumab, in atopic dermatitis and additional data for dupilumab are expected in allergic asthma later this month."

Regeneron Q1 net income increases [Published Individual.com - May 17 2013]

..." Mr. Silver continues, "Since the beginning of the year, ADVENTRX Pharmaceuticals (NYSE MKT: ANX) has seen its share priceprice rise approximately 35% and Power Solutions International (OTCQB: PSIX) is up over 25%. We believe investor appetite for stocks versus bonds could continue which may bolster small and micro-cap stocks."

OHR PHARMACEUTICAL INC : Vista Partners Publishes February 2013 Macroeconomic & Investment Newsle ... [Published 4 Traders - May 16 2013]

...ADVENTRX's stock price has risen nearly 39% in 2013." Mr. Silver also states, "Power Solutions International (OTCQB: PSIX) closed at a new 52-Week high of $22 last week and their stock price has risen approximately 30% in 2013. PSIX reported strong 4th quarter and year-end earnings results on Thursday and gave revenue guidance for 2013 & 2014. PSIX's revenue guidance for 2014 is targeted to be in a range of $310 to $330 million, a near 60% increase versus 2012 revenues taking the midpoint of sales guidance."

OHR PHARMACEUTICAL INC : Vista Partners Publishes March 2013 Macroeconomic & Investment Newsletter [Published 4 Traders - May 16 2013]

More Content

sort by: Date \| Relevance
Here's Why Amgen Shares Are Worth $117 To $126 ... [Published Seeking Alpha - 7 hours ago]
Comparative toxicity and proliferation testing ... [Published British Journal of Ophthalmology - 10 hours ago]
IBD 50 Stocks Delivering Strong Earnings, Sales... [Published Investors Business Daily - 12 hours ago]
Top Pre-Market Stock Upgrades/Downgrades May 17... [Published Wall Street Pit - 22 hours ago]
Stock Analysts’ New Coverage for May, 17th (AIP... [Published American Banking News - 23 hours ago]
Regeneron Q1 net income increases [Published Individual.com - May 17 2013]
Late-Day Pullback Leads To Lower Close On Wall ... [Published FinanzNachrichten.de - May 16 2013]
Only 12% of Public Biotechs are Profitable [Published I Am Biotech - May 16 2013]
Stocks Close Modestly Lower On Late-Day Pullbac... [Published RTTNews.com - May 16 2013]
Regeneron acquires rights to two antibodies for... [Published Individual.com - May 16 2013]
The Zacks Analyst Blog Highlights: Genomic Heal... [Published Yahoo! Finance - May 16 2013]
Top New Biotech Ideas from PropThink [Published 24/7 Wall St - May 16 2013]
OHR PHARMACEUTICAL INC : Vista Partners Publish... [Published 4 Traders - May 16 2013]
OHR PHARMACEUTICAL INC : Vista Partners Publish... [Published 4 Traders - May 16 2013]
Sanofi/Regeneron begin two more trials for RA drug [Published Pharma Times - May 16 2013]
Sanofi, Regeneron begin patient enrollment in O... [Published PharmaBiz - May 16 2013]
Sanofi and Regeneron's Latest Partnership [Published Daily Finance - May 16 2013]
Sanofi/REGN Commence Enrollment Zacks [Published Yahoo! Finance - May 15 2013]
Cramer: Buy Aqua America, Radian, Regeneron, an... [Published Wall St. Cheat Sheet - May 15 2013]
MARKET PULSE-SunPower, Apollo Investment, Comst... [Published London South East - May 15 2013]
MARKET PULSE-SunPower, Apollo Investment, Comst... [Published Yahoo! UK and Ireland - May 15 2013]
US EQUITIES OPENING HEADLINES INCLUDING: Wal-Ma... [Published Proactiveinvestors United Kingdom RSS feed - May 15 2013]
Sanofi and Regeneron Announce Patient Enrollmen... [Published Healthcare Sales & Marketing Network - May 15 2013]
Deutsche Bank Firm on Biotech Stocks to Buy [Published 24/7 Wall St - May 15 2013]
Sanofi and Regeneron Announce Patient Enrollmen... [Published Equities.com - May 15 2013]
Sanofi (SNY), Regeneron (REGN) Commence COMPARE... [Published Street Insider - May 15 2013]
Sanofi, Regeneron Announce Patient Enrollment i... [Published Benzinga.com - May 15 2013]
Sanofi et Regeneron annoncent le recrutement de... [Published Equities.com - May 15 2013]
Sanofi recruits patients for arthritis trials [Published Yahoo! News - May 15 2013]
Sanofi recruits patients for arthritis trials [Published Reuters - May 15 2013]

Blogs

sort by: Date \| Relevance
Top Pre-Market Stock Upgrades/Downgrades May 17... [Published Wall Street Pit - 22 hours ago] UPGRADESGeneral Motors (NYSE:GM) upgraded to Buy from Underperform at CLSA ? CLSA upgraded General Motors two notches to Buy from Underperform and raised its price target for shares to $40 from $31. The firm is positive on GM?s product cycle in the U.S. ...
Only 12% of Public Biotechs are Profitable [Published I Am Biotech - May 16 2013] Only 12% of Public Biotechs are Profitable Of the 286 biotech companies trading on public exchanges today, 241 focus on drug development, a slight drop in numbers from last year.* Of these 241 in the biopharmaceutical space, only 28 (12%) had both ...
Cramer: Buy Aqua America, Radian, Regeneron, an... [Published Wall St. Cheat Sheet - May 15 2013] Jim Cramer made the following calls on May 14th, 2013. What do you think about his picks? Aqua America ( NYSE:WTR ): Jim Cramer ranked this stock a Buy . Cramer previously ranked this stock a Buy on March 4, 2013. The stock’s 52-week high is $33.28, ...
R&D Spending may not be ALL Bad [Published The Big Red Biotech Blog - May 09 2013] Fierce Biotech yesterday reported that R&D spending was up as many significant biotechs -- like Gilead, Amgen, Celgene, Shire, Regeneron, Onyx and Biomarin. In other words, many of the darlings of biotech investors -- companies who have experienced significant ...
Bed Bath & Beyond CFO Sells 125K Shares and 4 I... [Published Wall St. Cheat Sheet - May 09 2013] Castagna Eugene A who is CFO and Treasurer at Bed Bath & Beyond, Inc. ( NASDAQ:BBBY ), sold 125,000 shares at $70.13 per share for a total value of $8,766,088. The shares recently traded at $69.26, down $0.87, or 1.24% since the insider sale.NEW! ...

Press Releases

sort by: Date \| Relevance
Sanofi and Regeneron Announce Patient Enrollmen... [Published PR Newswire: Health - May 15 2013]
Regeneron Announces Upcoming 2013 Investor Conf... [Published PR Newswire: General Business - May 08 2013]
Regeneron Reports First Quarter 2013 Financial ... [Published Financial Services - May 03 2013]
Regeneron Acquires Full Rights to Two Novel Oph... [Published Financial Services - May 03 2013]
BioNJ To Host 2ND Annual Life Sciences Industry... [Published Business Wire - Apr 30 2013]